Multifocal periungual granulation tissue related to ibrutinib therapy

Multifocal periungual granulation tissue related to ibrutinib therapy

Bibliographic Details
Main Authors:	Aatman Shah, MD, Anneli Bowen, MD, Christopher Hansen, MD
Format:	Article
Language:	English
Published:	Elsevier 2020-02-01
Series:	JAAD Case Reports
Subjects:	GVHD ibrutinib
Online Access:	http://www.sciencedirect.com/science/article/pii/S235251261930712X

Similar Items

Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia
by: Josh A. Hammel, MD, et al.
Published: (2017-05-01)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020-08-01)

The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
by: Ahmet Sarıcı, et al.
Published: (2023-05-01)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
by: Benjamin Arthurs, MD, et al.
Published: (2017-01-01)

Ventricular Tachycardia Storm in a Patient Treated With Ibrutinib for Waldenstrom Macroglobulinemia
by: Anantha Sriharsha Madgula, MBBS, et al.
Published: (2020-09-01)

Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib
by: Anna Christoforidou, et al.
Published: (2018-05-01)

Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

Development and Characterization of Ibrutinib-Loaded Ethylcellulose-Based Nanosponges: Cytotoxicity Assay against MCF-7 Cell Lines
by: Farhat Fatima, et al.
Published: (2023-04-01)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01)

Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)

Ibrutinib-associated atrial fibrillation treatment with catheter ablation
by: Ridhima Kapoor, MD, et al.
Published: (2021-11-01)

İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu
by: Aynur Uğur Bilgin, et al.
Published: (2017-03-01)

The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment
by: Giorgio Santoni, et al.
Published: (2022-01-01)

Synergistic Inhibition of Burkitt’s Lymphoma with Combined Ibrutinib and Lapatinib Treatment
by: Chae-Eun YANG, et al.
Published: (2023-12-01)

Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia
by: Haya Jamali, et al.
Published: (2023-05-01)

Imbruvica (Ibrutinib) induced subcutaneous hematoma: A case report
by: Chinmay Jani, et al.
Published: (2021-03-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

Approaches to the prevention and therapy of ibrutinib-associated bleeding in adult patients
by: E. V. Volchkov, et al.
Published: (2018-10-01)

Ibrutinib-related uveitis: A case series
by: Zelia K. Chiu, et al.
Published: (2022-03-01)

Alternative analytical methods for ibrutinib quantification in pharmaceutical formulation: A statistical comparison
by: Akbel Erten, et al.
Published: (2022-07-01)

Recurrent Cellulitis Revealing Helicobacter cinaedi in Patient on Ibrutinib Therapy, France
by: Anne-Laure Roupie, et al.
Published: (2023-03-01)

Safety and efficacy of ibrutinib in a patient with severe renal impairment
by: Kalman Filanovsky, et al.
Published: (2017-09-01)

Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
by: Nataliya Mar, et al.
Published: (2023-05-01)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
by: Walter Hanel, et al.
Published: (2023-02-01)

Ibrutinib-Associated multifocal paronychia with periungual pyogenic granulomas involving concomitant finger and toe nails
by: Lovleen Kaur, et al.
Published: (2023-01-01)

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
by: Samip Master, et al.
Published: (2017-06-01)

Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
by: Anna Mair, et al.
Published: (2021-09-01)

Formation of ibrutinib solvates: so similar, yet so different
by: Jan Jirát, et al.
Published: (2023-03-01)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
by: Denlinger NM, et al.
Published: (2018-03-01)

Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
by: Danuta Krasowska, et al.
Published: (2020-09-01)

Cystoid macular edema secondary to ibrutinib
by: Ravid Ben-Avi, et al.
Published: (2022-06-01)

The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy
by: Marco A. Mascarella, et al.
Published: (2019-10-01)

Preparation and Optimization of Ibrutinib-Loaded Nanoliposomes Using Response Surface Methodology
by: Fareeaa Ashar, et al.
Published: (2022-09-01)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
by: Keisuke Kidoguchi, et al.
Published: (2021-02-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
by: Jin Wang, et al.
Published: (2017-07-01)

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
by: Anıl Tombak, et al.
Published: (2021-12-01)

Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
by: Dong R, et al.
Published: (2022-09-01)

Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
by: Abdulkadir Erçalışkan, et al.
Published: (2022-11-01)